LEAVE BLANK 
Protocol No . ; IRB#900850-E 
New Project FDA-IND/IDE?^/ IL-2 Cetus 1969 Date of Approval: 
Continuation of IL-4 Sterling 2989 Non-approval: 
Renewal TIL: 2472 Reviewers: 
Transduced Tils : 3042/NSC622283 
Previous IRB Numbers: 
Date of Submission: August 3, 1990 
Title: The Treatment of Patients with Melanoma Using Interleukin- 2 , 
Interleukin-4 and Tumor Infiltrating Lymphocytes 
Principle Investigator: Michael T. Lotze , M. D, 
Signature: ( j^ 
Rank: Professor of Surgery 
Office Address: 497 Scaife Hall 
School: Medicine, University of Pittsburgh 
Telephone: 412-648-9489 
Co- investigators : 
Associate 
investigators : 
Joshua T. Rubin, M.D. 
Howard D. Edington, M.D. 
Mitchell C. Posner, M.D. 
Norman Wolmark, M.D. 
Ronald B. Herberman, M.D. 
Theresa L. Whiteside, Ph.D. 
Elaine Elder, Ph.D. 
Linda Dudjak, R.N. , M.S.N. 
James Snyder, M.D. 
Luke Chelluri, M.D. 
Kathy Hayes, R.N., M.N. 
John M. Kirkwood, M.D. 
Marc Ernstoff, M.D. 
Daniel R. Vlock, M.D. 
Barry Lembersky, M.D. 
Joseph Glorioso, Ph.D. 
William Futrell, M.D. 
Samuel Yousem, M.D. 
Robert Moen, M.D. 
French Anderson, M.D. Natl. 
Roger Day 
Surgical Oncology 
Surgical Oncology 
Surgical Oncology 
Surgical Oncology 
PCI, Director 
PCI, Immuno. Monitoring 
PCI, Immuno. Monitoring 
PCI 
Critical Care Medicine 
PCI-ICU 
PUH-Oncology Nursing 
PCI , Medical Oncology 
PCI , Medical Oncology 
PCI , Medical Oncology 
PCI , Medical Oncology 
Molec. Genetics & Biochem. 
Plastic Surgery 
Anat. Pathology 
Genetic Therapy Inc. 
Heart, Lung & Blood Inst. 
PCI, Biostatistics 
Source of Support: 
Pittsburgh Cancer Institute, Sterling Pharmaceutical 
Level of Risk: (circle one) High Moderate Minimal 
Number of Subjects? £0 Duration of study? 5 years 
Are normal subjects involved? yes x no 
Are children involved? yes x no 
Does this proposal qualify for expedited review? yes x no 
Has this proposal been or is it being submitted to other committees? 
X y es no (Approval pending) . 
[834] 
Recombinant DNA Research, Volume 14 
